Navigation Links
Poniard Announces Positive First-Line Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in Patients with Metastatic Hormone Refractory Prostate Cancer
Date:5/31/2008

y prednisone (5 mg) as a first-line treatment is being evaluated in 30 patients with metastatic HRPC. PSA response (defined as a PSA reduction of at least 50 percent from baseline) is the primary endpoint; secondary endpoints include safety, response rate, time to progression and overall survival. The trial completed enrollment in December 2007.

Results to date have shown a PSA response in 18 of 26 (69 percent) evaluable patients. Furthermore, PSA levels have normalized in six patients (21 percent). The combination of picoplatin and docetaxel can be safely administered with manageable and reversible neutropenia as the main hematologic toxicity. These data confirm earlier results observed in the Phase 1 trial. In contrast to picoplatin monotherapy, thrombocytopenia was less severe and less frequent. Neurotoxicity has not been observed in this study.

About Picoplatin

Picoplatin has an improved safety profile relative to existing platinum-based cancer therapies and is designed to overcome platinum resistance associated with chemotherapy in solid tumors. It is being studied in multiple cancer indications, combinations and formulations. Picoplatin has been evaluated in more than 750 patients and has demonstrated anti-tumor activity in multiple indications with less severe kidney toxicity (nephrotoxicity) and nerve toxicity (neurotoxicity) than is commonly observed with other platinum chemotherapy drugs.

In addition to the ongoing Phase 2 clinical trial in HRPC, Poniard is evaluating intravenous picoplatin in an ongoing pivotal Phase 3 trial, known as SPEAR (Study of Picoplatin Efficacy After Relapse), in small cell lung cancer. This registration trial currently is being conducted under a Special Protocol Assessment (SPA) from the U.S. Food and Drug Administration and is evaluating overall survival as the primary endpoint. Picoplatin is also being evaluated in an ongoing Phase 2 clinical trial in patients with metastatic colorectal cancer. Oral
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting
2. Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute
3. Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin Trial in Colorectal Cancer
4. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
5. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
6. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
7. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
8. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
9. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
10. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
11. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... , May 22, 2013 Ranbaxy Laboratories ... Co., Ltd. (hereafter, Daiichi Sankyo), announced on May ... recent years to address past conduct under prior ... Daiichi Sankyo continues to support Ranbaxy ... conduct of the past which led to the ...
(Date:5/22/2013)... 22. Mai 2013  Grifols, ein globales ... Barcelona , Spanien, präsentierte die ... höhere Dosis von PROLASTIN©-C (Alpha1-Proteinasehemmer [human]) den ... (AAT) auf ein Niveau anhebt, das innerhalb ... liegt. ATT-Mangel ist eine lebensbedrohliche, genetische Erkrankung, ...
(Date:5/22/2013)... and REHOVOT, Israel , May 22, ... ), a leading developer and provider of microRNA-based molecular ... , President and Chief Executive Officer of Rosetta Genomics, ... Healthcare Conference taking place from June 3-6, 2013 in ... on Tuesday, June 4 th at 2:00 p.m. ...
Breaking Medicine Technology:Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 2Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 3Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 4Rosetta Genomics to Present at the Jefferies 2013 Healthcare Conference 2Rosetta Genomics to Present at the Jefferies 2013 Healthcare Conference 3
... N.J., Jan. 4, 2012   CANTEL MEDICAL CORP. ... CEO, will be presenting at the Needham & Company, ... scheduled for 9:20 AM ET on Wednesday, January 11, ... Q & A session immediately following the presentation. In ...
... marketers who need to calibrate multi-channel marketing and sales ... SyntheSight™ , a new proprietary pharmaceutical ... patent-pending IntelliScore™ , provides actionable insights ... answers. SyntheSight ...
Cached Medicine Technology:RMi Introduces SyntheSight™ Pharma Multi-Channel Optimization Suite 2RMi Introduces SyntheSight™ Pharma Multi-Channel Optimization Suite 3
(Date:5/22/2013)... WEDNESDAY, May 22 (HealthDay News) -- Fish oil ... 2 diabetes, new research suggests. The ... levels of a hormone called adiponectin that,s linked ... of this hormone in the bloodstream have also ... disease. "While prior animal studies found fish ...
(Date:5/22/2013)... at Massachusetts General Hospital (MGH) one of the ... half rated the training they had received in addiction ... Significant numbers felt unprepared to diagnose or treat such ... response to the findings, recently published online in the ... residents, training in addiction medicine. , "Our residents ...
(Date:5/22/2013)... effect does a father,s depression have on his young son ... intimacy in their marriage, their children benefit, said a University ... their child, they need to be able to attend to ... stage and abilities, and notice whether he is getting frustrated ... said Nancy McElwain, a U of I professor of human ...
(Date:5/22/2013)... A new study suggests that disturbed sleep in ... and greater uncertainly about future success. However, ... appears to have a protective effect. , ... with depressed mood and greater uncertainty about future ... and from teachers were associated with significantly fewer ...
(Date:5/22/2013)... "power plants" that make energy to keep cells alive ... of the drug-resistant forms of cancer source of ... conclusion of a new study published in the journal ... and colleagues explain that doxorubicin and other common forms ... nucleus of cancer cells. Cancer cells divide and multiply ...
Breaking Medicine News(10 mins):Health News:Fish Oil Pills Might Cut Diabetes Risk, Researchers Say 2Health News:Survey points out deficiencies in addictions training for medical residents 2Health News:Survey points out deficiencies in addictions training for medical residents 3Health News:Survey points out deficiencies in addictions training for medical residents 4Health News:Good marriage can buffer effects of dad's depression on young children 2Health News:Parent and teacher support protects teens from sleep problems and depression 2
... Perrigo Company,(Nasdaq: PRGO ; TASE) today announced ... present at the 12th Annual Sidoti Emerging Growth,Institutional ... p.m. (ET) at the,Grand Hyatt Hotel in New ... global healthcare supplier that develops,manufactures and distributes over-the-counter ...
... will be a covered benefit immediately upon its ... members with chronic lymphocytic leukemia, INDIANAPOLIS, March ... effective immediately upon the drug,s,availability, its affiliate health ... coverage for Treanda. Specific benefit plans,may have variable ...
... Natural,Nutrition, Inc. (OTC Bulletin Board: NTNI) ... Finance, Inc., has been,renamed i-Nutrition, Inc. As the ... lending activities of CSI Business Finance have been ... all proceeds from loan payments,received going forward will ...
... Medicine and the Fox Chase Cancer Center have announced ... to join the Temple faculty and train Temple graduate ... share strengths and resources to collaborate on a new ... to those made between other medical schools and cancer ...
... Sharps Compliance Corp.,(OTC Bulletin Board: SCOM) ("Sharps" ... for small quantity generators of,medical waste, announced today ... Senior Vice President of Operations. Mr. Aladwani joins ... developer and,manufacturer of medical devices, where he served ...
... Southwestern Medical Center Patients Will Be the First to Benefit ... ... HOFFMAN ESTATES, Ill., March 24 Siemens Healthcare, (http://www.siemens.com/healthcare ) ... technology at UT Southwestern Medical,Center in Dallas. The facility will ...
Cached Medicine News:Health News:WellPoint's Health Plans to Cover Newly Approved Cancer Treatment 2Health News:Natural Nutrition Renames Former Business Lending Subsidiary i-Nutrition, Inc. 2Health News:Temple and Fox Chase partner on research and education 2Health News:Temple and Fox Chase partner on research and education 3Health News:Temple and Fox Chase partner on research and education 4Health News:Sharps Compliance Corp. Announces Appointment of Al Aladwani as its Senior Vice President of Operations 2Health News:Sharps Compliance Corp. Announces Appointment of Al Aladwani as its Senior Vice President of Operations 3Health News:Siemens Installs First High-Definition PET-CT 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: